A Triple-RBD-Based Mucosal Vaccine Provides Broad Protection against SARS-CoV-2 Variants of Concern

Researchers designed a chimeric triple-RBD immunogen, 3Ro-NC, harboring one Delta RBD and two Omicron RBDs within a novel protein scaffold. 3Ro-NC elicited potent and broad RBD-specific neutralizing immunity against SARS-CoV-2 variants of concern.